Ishita Drugs and Industries Ltd.
Financial Performance Summary (FY 2025-26)
- Total Revenue: ₹1513.34 lakhs (Previous Year: ₹1533.30 lakhs) - decrease of 1.30%
- Operating Gross Profit: ₹123.88 lakhs (PY: ₹133.72 lakhs)
- Financial Charges: ₹5.92 lakhs (PY: ₹7.22 lakhs)
- Depreciation: ₹9.96 lakhs (PY: ₹10.98 lakhs)
- Profit Before Tax: ₹108.00 lakhs (PY: ₹115.51 lakhs)
- Provision for Income Tax: ₹30.09 lakhs (PY: ₹29.50 lakhs)
- Provision for Deferred Tax: ₹0.07 lakhs (PY: ₹0.79 lakhs credit)
- Net Profit: ₹77.85 lakhs (PY: ₹86.81 lakhs) - decrease of 10.32%
The decrease in profit is attributed to increased expenses towards repairs and renovation of factory buildings for the Schedule M upgradation project.
Share Capital Structure
- Authorized Share Capital: ₹6,00,00,000 divided into 60,00,000 equity shares of ₹10 each
- Paid-up Capital: ₹2,99,03,000 divided into 29,90,300 equity shares of ₹10 each (unchanged from previous year)
- No dividend recommended for FY 2025-26 due to fund requirements for facility upgradation
33rd Annual General Meeting Details
- Date: Wednesday, 30th September 2026
- Time: 11:30 AM
- Venue: "Manthan", Hotel Krsna Lila, Nr. Rexroth Bosch, Village Iyava, Taluka Sanand, Sanand Viramgam Highway, Gujarat 382170
- Book Closure: 24th September 2026 to 30th September 2026 (both days inclusive)
Agenda Items
Ordinary Business
1. Adoption of audited financial statements for FY ended 31st March 2026 with reports of Board of Directors and Auditors
2. Re-appointment of M/s Jaymin Shah & Associates, Chartered Accountants (FRN: 129406W) as Statutory Auditors for one year
Special Business
3. Special Resolution: Re-appointment of Mrs. Abha Agrawal (DIN: 01589479) as Non-Executive Non-Independent Director post attaining age of 75 years
4. Ordinary Resolution: Approval of related party transactions with Ishita Pharmaceuticals
5. Ordinary Resolution: Approval of related party transactions with Anvi Lifesciences Private Limited
Related Party Transactions
Transactions with related parties Ishita Pharmaceuticals and Anvi Lifesciences Private Limited may exceed 10% of the annual turnover threshold and require shareholder approval under Regulation 23 of SEBI (LODR) Regulations, 2015. All transactions are stated to be at arm's length and in the ordinary course of business.
Facility Upgradation Project
The company is undertaking a major manufacturing facility upgrade to comply with Revised Schedule M requirements:
- ₹54.87 lakh spent on building repairs
- ₹174.73 lakh spent on new buildings
- ₹58.30 lakh worth of equipment and utilities ordered, with ₹13.69 lakh paid as advances
- The company plans to raise debt to partially fund this project
- Once upgraded, the facility will enable export to semi-regulated/regulated markets and introduction of newer products
Corporate Governance
- Board comprises 4 directors: 2 Independent, 1 Non-Executive Promoter, and 1 Managing Director
- 5 Board meetings held during the year
- Committees: Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee
- No pending investor complaints as of 31st March 2026
Auditors and Compliance
- Statutory Auditors: M/s Jaymin Shah & Associates - unqualified audit report
- Secretarial Auditor: M/s Meenu Maheshwari & Associates - no qualifications or adverse remarks
- Company states compliance with all applicable laws and regulations
Shareholding Pattern (as on 31st March 2026)
- Promoter holding: 50.04% (increased from 49.91%)
- Public holding: 49.96%
- 85.90% shares held in dematerialized form
Key Management Personnel
- Mr. Jagdish Agrawal (Managing Director): Remuneration ₹51,00,000
- Mr. Sumit Agrawal (CFO): Remuneration ₹31,80,000
- Mrs. Abha Agrawal (Director): No remuneration
Other Material Information
- No material changes or commitments affecting financial position post year-end
- No significant/material orders passed by regulators or courts
- Company has adequate internal financial controls
- Foreign exchange earnings: ₹75.76 lakhs (PY: ₹66.46 lakhs)
- Foreign exchange outgo: ₹30.31 lakhs (PY: ₹564.93 lakhs)